|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Neither the presence of ascites (6.6% complications) nor of coagulopathy (platelets<50G/L and/or prothrombin time<50%; 4.8% complications) increased the risk for complications.
|
30862438 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We defined coagulopathy as EXTEM clot amplitude at 5 min (A5) < 40 mm or prothrombin ratio > 1.5.
|
29743045 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We assessed the performance of prothrombin time (PT) at point-of-care in trauma patients to detect moderate and severe coagulopathy on admission.
|
29707780 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Congenital rare bleeding disorders RBD are reported in most populations, with incidence varying from 1 in 5000 (Hemophilia A), 1:30,000 (Hemophilia B) to much rarer (1:500,000 for FVII deficiency, 1-3 million for Prothrombin or FXIII deficiency).
|
28222949 |
2017 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The routine screening tests for coagulopathies-prothrombin time, activated partial thromboplastin time, and thrombin time-do not show abnormalities in cases of FXIII deficiency.
|
24476525 |
2014 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Prothrombin (factor II) deficiency is a rare autosomal recessive coagulation disorder that occurs in approximately 1 in 1-2 million people.
|
19141155 |
2008 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Furthermore, we studied the risk of myocardial infarction associated with the simultaneous presence of a coagulation defect (ie, the 20210 AG genotype of prothrombin or the factor V Leiden mutation) and Major cardiovascular risk factors.
|
9531249 |
1998 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Hereditary deficiency of prothrombin is a rare autosomal recessive bleeding disorder, with severe bleeding diathesis in homozygotes, but rarely resulting in intracranial haematoma.
|
10706027 |
1999 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder.
|
7740448 |
1994 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We present a case of a 15-month-old female infant with type I biliary atresia with jaundice (total serum bilirubin, 22.2 mg/dL), hypoalbuminemia (serum albumin level, 2.58 g/dL), coagulopathy (prothrombin time > 20 s compared with that of a normal control), ascites, splenomegaly, portal hypertension (portal vein velocity, 3.9-5.6 cm/sec of hepatopetal flow), and repeated bleeding of the varices after receiving three doses of intravascularly administered Histoacryl 1 ampoule mixed with Lipiodol UF 8 mL in the EV.
|
30819091 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We identified this bleeding disorder in a US-born patient as due to prothrombin Puerto Rico I.
|
17160994 |
2007 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Compound heterozygosity for two novel missense mutations in the prothrombin gene in a patient with a severe bleeding tendency.
|
9134629 |
1997 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Compared with that of human prothrombin, variation at critical recognition sites would likely alter its binding affinity and reaction velocity, which would contribute to coagulation disorder when porcine liver is transplanted into human body.
|
17188533 |
2007 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Utility of prothrombin complex concentrate as first-line treatment modality of coagulopathy in patients undergoing liver transplantation: A propensity score-matched study.
|
30375084 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Understanding the mechanism of action of normal hemostasis and how the bypassing agents recombinant activated factor VII (rFVIIa; NovoSeven) and plasma-derived activated prothrombin complex concentrate (Factor Eight Inhibitor Bypassing Agent [FEIBA]) control abnormal bleeding is imperative for healthcare professionals who treat patients with hemophilia and other bleeding disorders.
|
22632160 |
2012 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In conjunction with routine diagnostics for injury and disease, we performed two blood clotting assays (prothrombin time, Russell's viper venom time) affected by vitamin K-dependent coagulopathy of samples from six species of live raptors admitted to a rehabilitation facility.
|
30677887 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Factor concentrates, specifically prothrombin complex concentrates (PCCs), are often used as part of multimodal therapy for bleeding along with laboratory testing to rapidly assess underlying coagulopathy.
|
31537028 |
2020 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Prothrombin complex concentrate (PCC) is increasingly used to correct acquired coagulopathy in trauma and surgery.
|
30236256 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The rarest of reported inherited plasmatic coagulopathies involve prothrombin.
|
625142 |
1978 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Prothrombin complex concentrates (PCC) treat inborn coagulation disorders and reverse oral anticoagulants, but are proposed for use in "factor-based" resuscitation strategies.
|
28700408 |
2017 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our analyses suggest that prothrombin concentration at admission is predictive of mortality and transfusion and indicates that prothrombin and fibrinogen are rate limiting in coagulopathy.
|
28292321 |
2017 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Prothrombin, alone or in complex concentrates or plasma, reduces bleeding in a mouse model of blood exchange-induced coagulopathy.
|
31506556 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Four-Factor Prothrombin Complex Concentrate for Coagulopathy Reversal in Patients With Liver Disease.
|
27628534 |
2017 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
This dogma was seemingly supported by abnormalities in standard laboratory tests (SLTs), such as the prothrombin time, that were interpreted as indicating a bleeding diathesis.
|
29027774 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Use of four-factor prothrombin complex concentrate in the reversal of warfarin-induced and nonvitamin K antagonist-related coagulopathy.
|
28604569 |
2017 |